BIOA
HEALTHCAREBioAge Labs Inc
$18.46+1.78 (+10.67%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BIOA Today?
No stock-specific AI insight has been generated for BIOA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.67$24.00
$18.46
Fundamentals
Market Cap$820M
P/E Ratio—
EPS$-2.24
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume588K
Avg Volume (10D)—
Shares Outstanding44.4M
BIOA News
20 articles- BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC TrialsMarketbeat·May 8, 2026
- BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business UpdatesYahoo Finance·May 8, 2026
- BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026Yahoo Finance·May 4, 2026
- BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety ProfileMarketbeat·Apr 24, 2026
- Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?Yahoo Finance·Apr 23, 2026
- Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should KnowYahoo Finance·Apr 21, 2026
- BioAge says early data suggest ‘best-in-class’ potential for inflammation drugBiopharmadive·Apr 21, 2026
- BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRPYahoo Finance·Apr 21, 2026
- BioAge Labs Highlights BGE-102 Catalysts, DME Study Plans and $285M Cash at Needham ConferenceMarketbeat·Apr 16, 2026
- BioAge Labs to Present at 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 13, 2026
- Is Amgen (AMGN) Outperforming Other Medical Stocks This Year?Yahoo Finance·Apr 7, 2026
- BGE-102 Data Inspires Confidence for BioAge Labs (BIOA)Yahoo Finance·Mar 31, 2026
- BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025Yahoo Finance·Mar 24, 2026
- New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congressYahoo Finance·Mar 23, 2026
- BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal ExpansionMarketbeat·Feb 27, 2026
- BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceYahoo Finance·Feb 19, 2026
- BLA for subcutaneous formulation of Leqembi® designated for Priority Review in ChinaYahoo Finance·Feb 9, 2026
- Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potentialPharmavoice·Jan 29, 2026
- BioAge Announces Pricing of Upsized $115.0 Million Public OfferingYahoo Finance·Jan 22, 2026
- Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Amid Continued Tariff Threats, Investors Await President Trump's Speech at DavosYahoo Finance·Jan 21, 2026
All 20 articles loaded
Price Data
Open$16.84
Previous Close$16.68
Day High$18.81
Day Low$16.55
52 Week High$24.00
52 Week Low$3.67
52-Week Range
$3.67$24.00
$18.46
Fundamentals
Market Cap$820M
P/E Ratio—
EPS$-2.24
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume588K
Avg Volume (10D)—
Shares Outstanding44.4M
About BioAge Labs Inc
BioAmber Inc., an industrial biotechnology company, produces and sells bio-succinic acid to various customers in the chemical market primarily in the United States and Canada. The company is headquartered in Montreal, Canada.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—